This research develops a targeted anti-VEGF therapy for wet age-related macular degeneration that can be injected under the skin rather than directly into the eye. In animal studies, the drug successfully reached the eye and reduced abnormal blood vessel growth, offering a safer, cheaper, and more convenient treatment for preventing blindness.

This research improves drug formulations by developing predictive tools for amorphous solid dispersions that increase drug solubility while allowing higher drug loading in a single tablet. The work aims to reduce pill burden, improve medication adherence, lower pharmaceutical development costs, and make treatments more effective for patients with chronic illnesses.

This research develops hybrid lipo-polymeric nanoparticles that overcome major limitations of current mRNA vaccine technology. The particles can be freeze-dried, rapidly loaded with mRNA, and simultaneously deliver therapeutic drugs. Their flexibility improves vaccine storage and distribution while enabling powerful combination therapies, including enhanced cancer treatments with improved survival in preclinical models.

This research investigates how bacterial biofilms alter the mechanical properties of infected skin to improve microneedle-based drug delivery. By measuring tissue stiffness, structural integrity, and puncture resistance, it provides the evidence needed to design microneedles that can effectively penetrate biofilms, deliver antibiotics directly, and improve treatment of chronic wound infections.

This research engineers DNA-modified exosomes to deliver drugs precisely to cancer cells while avoiding healthy tissue. By disguising natural cell-targeting signals and adding programmable DNA targeting molecules, the platform could reduce treatment side effects and provide a modular delivery system adaptable to many cancers and other diseases.

This research engineers peptide-based "drug cages" that assemble like molecular zippers to deliver medicines only at their intended target. Inspired by natural protein structures, these programmable nanostructures could dramatically reduce chemotherapy side effects by releasing drugs precisely where needed, improving treatment effectiveness while protecting healthy tissues.

This research develops orally administered nanoparticles that target the lymphatic system to treat lupus and osteoporosis simultaneously. By delivering drugs directly to affected tissues while avoiding the bloodstream, the approach reduces toxicity, suppresses inflammatory and bone-damaging genes, and offers a more effective strategy for treating these complex chronic diseases.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.

This research develops targeted lipid nanoparticle delivery systems to improve tuberculosis treatment and vaccination. By replacing PEG coatings and using mannose to target infected macrophages, it aims to deliver drugs more effectively, reduce treatment duration, improve vaccine performance, and contribute to the global elimination of tuberculosis.

This research develops innovative three-dimensional "daisy" particle structures to improve inhaled medicines. Using Isothermal Dry Particle Coating, it prevents fine drug particles from clumping, ensuring they reach the lungs effectively. The work aims to improve inhaler performance and treatment for the 300 million people worldwide living with respiratory diseases.